GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Bought by Sanctuary Advisors LLC

Sanctuary Advisors LLC lifted its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 29.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,761 shares of the company’s stock after buying an additional 4,738 shares during the period. Sanctuary Advisors LLC’s holdings in GE HealthCare Technologies were worth $1,948,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GEHC. Assenagon Asset Management S.A. grew its holdings in GE HealthCare Technologies by 8.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 12,479 shares of the company’s stock valued at $972,000 after buying an additional 953 shares in the last quarter. Raymond James & Associates lifted its stake in shares of GE HealthCare Technologies by 10.4% in the 2nd quarter. Raymond James & Associates now owns 381,702 shares of the company’s stock valued at $29,742,000 after purchasing an additional 36,076 shares during the last quarter. Fifth Third Bancorp grew its holdings in shares of GE HealthCare Technologies by 2.3% during the 2nd quarter. Fifth Third Bancorp now owns 33,343 shares of the company’s stock worth $2,598,000 after purchasing an additional 734 shares during the period. Atria Wealth Solutions Inc. increased its position in shares of GE HealthCare Technologies by 2.4% during the 2nd quarter. Atria Wealth Solutions Inc. now owns 37,472 shares of the company’s stock worth $2,920,000 after purchasing an additional 879 shares during the last quarter. Finally, Avitas Wealth Management LLC acquired a new position in GE HealthCare Technologies in the second quarter valued at about $1,517,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at GE HealthCare Technologies

In other news, CEO Roland Rott sold 3,577 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total value of $309,338.96. Following the transaction, the chief executive officer now owns 24,298 shares of the company’s stock, valued at approximately $2,101,291.04. The trade was a 12.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.27% of the stock is owned by company insiders.

GE HealthCare Technologies Trading Down 2.7 %

NASDAQ:GEHC opened at $77.09 on Thursday. The company has a quick ratio of 0.98, a current ratio of 1.23 and a debt-to-equity ratio of 1.12. GE HealthCare Technologies Inc. has a 52-week low of $71.31 and a 52-week high of $94.55. The stock’s 50 day moving average price is $85.14 and its 200 day moving average price is $83.75. The company has a market capitalization of $35.22 billion, a PE ratio of 21.18, a P/E/G ratio of 2.96 and a beta of 1.07.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.06 by $0.08. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The firm had revenue of $4.86 billion during the quarter, compared to the consensus estimate of $4.87 billion. During the same quarter in the prior year, the firm earned $0.99 EPS. GE HealthCare Technologies’s revenue for the quarter was up .9% on a year-over-year basis. On average, research analysts anticipate that GE HealthCare Technologies Inc. will post 4.3 EPS for the current year.

GE HealthCare Technologies Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Tuesday, January 14th will be given a $0.035 dividend. This represents a $0.14 annualized dividend and a yield of 0.18%. The ex-dividend date of this dividend is Tuesday, January 14th. This is a boost from GE HealthCare Technologies’s previous quarterly dividend of $0.03. GE HealthCare Technologies’s payout ratio is 3.85%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on GEHC shares. Stifel Nicolaus boosted their price target on shares of GE HealthCare Technologies from $100.00 to $102.00 and gave the company a “buy” rating in a research note on Monday, September 30th. UBS Group cut GE HealthCare Technologies from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $84.00 to $74.00 in a research note on Thursday, September 26th. JPMorgan Chase & Co. assumed coverage on GE HealthCare Technologies in a research note on Monday, September 9th. They issued a “neutral” rating and a $90.00 price objective for the company. Wells Fargo & Company raised their target price on GE HealthCare Technologies from $95.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Finally, BTIG Research upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research note on Wednesday, September 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, GE HealthCare Technologies has an average rating of “Moderate Buy” and a consensus price target of $95.46.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.